GN-HEARING
1.2.2021 09:02:06 CET | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound Key, a full essential hearing aid line-up that provides greater access to proven and award-winning hearing technology worldwide. Based on an advanced chip platform and GN’s Organic Hearing philosophy, ReSound Key promises clear, natural sound quality. It is also packed with the latest technology, such as rechargeable options and state-of-the-art streaming, so that more people can now stay connected to live life to the fullest.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005069/en/
Today, only one in five of those who could benefit from hearing aids are using themi , leaving a large proportion to miss out on life’s sounds, communicating with family, and socializing with friends. The long-awaited ReSound Key is set to make a huge difference to people with all types of hearing loss. People can boost their confidence and connect with others and the world during times of social isolation; all with clear sound and leading rechargeability that offers up to 30 hours of power from one charge. They can enjoy direct streaming using iOS and Android™ devices and state-of-the-art Bluetooth® Low Energy.
Not treating hearing loss comes at a personal cost, with implications for physical, social, emotional, and mental health.ii,iii,iv However, professional guidance is at hand, even remotely, thanks to the innovative telehealth solution, ReSound Assist Live. With this agile at-home service, hearing care professionals can program and adjust ReSound Key hearing aids via video consultations to help people grow with their hearing and nurture their relationships.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we believe that everyone deserves great hearing. Treating hearing loss can radically transform lives, helping people to thrive and grow. The launch of ReSound Key gives more people access to the best care and professional guidance, which helps them feel more confident and stay in touch with others to participate fully in life.”
ReSound Key joins the groundbreaking ReSound ONETM with M&RIE* and ReSound LiNX Quattro™ in the strongest and broadest ReSound portfolio yet, which offers premium hearing solutions at all price levels. Now more people can benefit from the company’s long-standing Organic Hearing philosophy to connect with the world around them in the most intuitive and natural way, which is inspired by how the ear works and the natural ways we listen.
Working with intuitive apps, ReSound Key further enhances the individualized hearing experience and can connect to a range of wireless accessories for additional help in challenging listening situations. New integrated, streamlined fitting and software updates ensure a seamless first fit and customer satisfaction. These updates make it easier than ever to offer the ReSound portfolio for users to enjoy.
ReSound Key is available in 10 models, including the popular rechargeable Receiver-in-Ear (RIE) design, custom hearing aids, and Behind-the-Ear (BTE) options – even including high power and super power models for profound hearing loss. ReSound Key will roll out in markets around the world from February 1, 2021. The same technology and models are also available in the new Beltone Rely hearing aid portfolio.
For further information, visit the ReSound Newsroom and learn about the Organic Hearing philosophy. A ReSound Virtual Conference is hosted for hearing care professionals in the United States on February 2, 2021.
– ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn and Facebook .
*ReSound ONE introduced the world’s first full-featured hearing aid with M&RIE. Microphone and Receiver In Ear, for a truly individualized, more complete sound experience. ‘Full-featured’ means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2021 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC. Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc
i World Health Organization (WHO) 2020: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
ii Hearing loss and incident dementia. Lin et al 2011
iii The impact of communication impairments on the social relationships of older adults: Pathways to psychological well-being. Palmer et al 2019
iv Hearing loss and associated medical conditions among individuals 65 years and older. McKee et al 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom